| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C17H18F2N6O2 |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
HAA-09 is an orally active anti-influenza agent that targets the PB2 cap-binding domain of the influenza polymerase. It shows potent activity against influenza A virus, with an EC50 of 0.03 μM, and inhibits the viral polymerase with an IC50 of 0.06±0.004 μM, blocking virus replication without evident cytotoxicity[1]. It has the molecular formula C17H18F2N6O2 and a molecular weight of 376.36 g/mol.
Physical & Chemical Properties
| CAS Number | 1422051-33-9 |
|---|---|
| Molecular Formula | C17H18F2N6O2 |
| Molecular Weight | 376.36 g/mol |
| SMILES | CC(C)(N(NC1=C(C=NC(C2=CNC3=C2C=C(C=N3)F)=N1)F)CC(O)=O)C |
| Signaling Pathway | Anti-infection |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
IC50: 0.06±0.004 μM (polymerase); EC50: 0.03 μM (influenza A virus)[1]
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
Against both oseltamivir-sensitive A/WSN/33 and the oseltamivir-resistant H275Y variant, HAA-09 shows stronger antiviral activity than oseltamivir[1].
In Vivo
HAA-09 displays high plasma stability (t1/2≥12 h) and no obvious hERG inhibition[1]. In mice, HAA-09 (0-25 mg/kg; Orally, BID) shows anti-influenza virus efficacy[1].
| Animal Model | Balb/C mice[1] |
|---|---|
| Dosage | 40 mg/kg |
| Administration | Orally, QD (once daily) for consecutive 3 days |
| Result | Demonstrated a favorable safety profile when orally administrated in healthy mice. |
| Animal Model | Female BALB/c mice (6–8 weeks)[1] |
|---|---|
| Dosage | 12.5, 25 mg/kg |
| Administration | Orally, BID (twice daily) starting 48 h post infection for 9 days |
| Result | Demonstrated in vivo therapeutic efficacy (85.7% survival observed at the day 15 post infection). |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
